

Postponement:

Injectable Mental Health Drugs and Billing Changes

Since the following agents are administered in a clinical setting, effective November 1, 2012, injectable mental health drugs, including but not limited to antipsychotics and benzodiazepines, become solely a medical benefit and are to be billed as such. ***As of November 1, 2012, these drugs will be closed to Pharmacy Point of Sale (POS).***

The only exceptions are for Medicaid only beneficiaries residing in long term care facilities such as nursing facilities (NF), intermediate-care facilities for the mentally retarded (ICF-MR), and/or psychiatric residential facilities (PRTF). ***All pre-existing pharmacy prior authorizations for injectable antipsychotics and/or benzodiazepines, except for the aforementioned exceptions, become null and void as of close of business on October 31, 2012.***

Injectable antipsychotics include, but are not limited to:

- Abilify (aripiprazole),
- Compazine (prochlorperazine edisylate)
- Geodon (ziprasidone),
- Haldol Lactate and Haldol Deconate Decanoate(compare to haloperidol lactate and haloperidol decanoate),
- Invega Sustenna (paliperidone palmitate),
- Prolixin decanoate (fluphenazine Decanoate)
- Risperdal Consta(risperidone microspheres),
- Thorazine (chlorpromazine HCL),
- Zyprexa (olanzapine), and
- Zyprexa Relprevv (olanzapine pamoate).

Injectable benzodiazepines include, but are not limited to:

- Lorazepam (compare to Ativan), and
- Diazepam (compare to Valium).